Hypertension remains one of the leading medical complications during pregnancy, contributing significantly to maternal and perinatal morbidity worldwide. Managing high blood pressure in expectant mothers requires agents that lower pressure effectively without compromising placental perfusion or harming the developing fetus. Methyldopa has served as a cornerstone agent in obstetric pharmacology for decades. Unlike many other blood pressure medications that cross the placenta with uncertain safety profiles, this drug possesses a long-established history of safe use in human pregnancy, particularly for chronic hypertension and gestational hypertension.
Methyldopa acts as a central nervous system agent. Once ingested, it is metabolized into alpha-methylnorepinephrine, a false neurotransmitter. This compound stimulates central alpha-2 adrenergic receptors in the brainstem, which dampens sympathetic outflow from the central nervous system. The reduction in sympathetic tone leads to a decrease in peripheral vascular resistance, lowering systemic blood pressure. Crucially, this mechanism typically preserves adequate blood flow to vital organs, including the uteroplacental unit.
The main indication for methyldopa is the management of hypertension diagnosed either before pregnancy or during the gestational period. It is frequently chosen when blood pressure readings consistently exceed safe thresholds (usually systolic above 140 mmHg or diastolic above 90 mmHg) and non-pharmacological measures are insufficient. While it effectively controls chronic hypertension, it is also utilized in non-severe gestational hypertension to prevent maternal complications like stroke while waiting for fetal maturity.
Treatment with methyldopa usually begins with a low dose, such as 250 mg orally two or three times a day, to minimize sudden sedative side effects. The total daily dose can be gradually increased every two days or as needed based on blood pressure response, up to a maximum daily limit typically around 3 grams. Midwives must ensure patients understand that blood pressure reduction occurs gradually over several hours rather than instantly.
Midwives play a vital role in educating pregnant women prescribed methyldopa. Counseling should include warning patients about initial drowsiness so they avoid hazardous activities like operating machinery. Midwives must emphasize the importance of taking medication consistently rather than stopping abruptly, as sudden cessation can trigger rebound hypertension. Routine antenatal assessments must combine blood pressure recording, urinalysis for protein, and inquiries about subjective symptoms like severe headaches or visual changes.